发作频率的变化和怀孕期间和怀孕后一年的抗发作药物治疗
Yanru Du1, Wenqiang Fang1, Wenting Huang1
1Department of Neurology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province, PR China.
Epilepsy & behavior : E&B
|May 27, 2023
概括
在遵循指导方针时,患者 (WWE) 妇女的控制在怀孕前,怀孕前和怀孕后期间保持稳定. 这项现实研究表明,在这些关键阶段,发作频率和药物调整都类似.
科学领域:
- 神经学 神经学
- 产科 产科 产科 产科 产科
- 药理学 药理学是指药理学的学科.
背景情况:
- 在怀孕期间患有 (WWE) 的妇女中,控制发作是一个关键的临床问题.
- 了解发作频率的变化和抗药物 (ASM) 治疗对于优化护理至关重要.
研究的目的:
- 为了比较WWE的发作频率和ASM治疗在三个时期:怀孕前,怀孕后和怀孕后.
- 分析现实世界关于发作控制和治疗调整在的孕妇的数据.
主要方法:
- 从第三级医院的病登记处 (2010-2020年) 追溯分析了249个WWE中的271个怀孕情况.
- 收集的数据为怀孕前12个月 (第1阶段),怀孕至产后6周 (第2阶段) 和产后6周至12个月 (第3阶段) 的数据.
- 发作被分类为性-克隆性/焦点到双边性-克隆性或非性-克隆性;记录了ASM治疗变化.
主要成果:
- 没收率为38.4% (第一时代),34.7% (第二时代) 和43.9% (第三时代),没有显著差异 (P = 0.09).
- 与第一阶段 (P = 0.02) 相比,第二阶段 (31.0%) 和第三阶段 (21.8%) 的非增强性-克隆性发作频率的增加更高.
- 在第二个时代 (35.8%) 与第三个时代 (27.3%) (P = 0.03) 相比,女性的ASM剂量增加的比例更高.
结论:
- 患有的孕妇的发作频率可能与怀孕前和怀孕后的时期没有显著差异,如果按照既定的指导方针进行管理.
- 现实世界的数据表明,遵守治疗方案可以在整个怀孕和产后期间保持控制.
- 调整ASM治疗是常见的,在怀孕期间和产后早期显著增加,突出需要警监测.
更多相关视频
10:22Interictal High Frequency Oscillations Detected with Simultaneous Magnetoencephalography and Electroencephalography as Biomarker of Pediatric Epilepsy
Published on: December 6, 2016
20.4K
09:29Continuous Video Electroencephalogram during Hypoxia-Ischemia in Neonatal Mice
Published on: June 11, 2020
3.4K
相关概念视频
01:24Epilepsy and Seizures: Overview
230
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
230
01:08Antiepileptic Drugs: Sodium Channel Blockers
699
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
699
01:20Antiepileptic Drugs: Potassium Channel Activators
221
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
221
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
354
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
354
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
474
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
474
01:17Antiepileptic Drugs: Calcium Channel Blockers
477
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
477